Asia-Pacific Lyophilized Injectable Market

The APAC lyophilized injectable market is expected to grow from US$ 673.33 million in 2022 to US$ 996.85 million by 2028. It is estimated to grow at a CAGR of 6.8% from 2022 to 2028.   

Advancement in Lyophilized Packaging

The complexity of drug reconstitution constrained the market potential for lyophilized drugs and vaccines. Multiple pieces of device and long procedures are required to reconstitute a lyophilized drug from a vial; thus, most of these products are restricted within healthcare facilities. However, the healthcare transformation toward patient self-injection and the acceleration after biologics flared a new wave of creation for drug reconstitution technology. Dual-chamber syringes represent an enabling technology for the self-injection of lyophilized drugs and new therapies directing the mixing of two liquid molecules at the time of drug delivery. Prefilled dual chamber devices (DCDs) are combination devices containing freeze-dried drugs and diluent in two separate chambers of the device. DCDs have shown many advantages, such as easy handling, accurate dosing, seal integrity, and high stability, compared to the traditional drug-delivery systems; therefore, they are promising alternatives to these traditional drug-delivery systems. DCDs are being increasingly preferred by physicians for patients needing instant relief and safe delivery, significantly improving drug delivery by quickly applying pressure to the end plunger after mixing and dissolving freeze-dried powder. DCDs can improve long-term pharmaceutical stability by storing them in the lyophilized form before administration and therefore are becoming more popular, especially for those unstable pharmaceutical products. Therefore, advancement in lyophilized packaging is expected to drive the market across the region.  

Market Overview

The APAC lyophilized injectable market is segmented into China, India, Japan, South Korea, Australia, and the Rest of APAC. China dominated the market in 2022. The market's growth is primarily attributed to the established pharmaceutical market, increased R&D expenditures by pharmaceutical and biopharmaceutical companies, and favorable regulatory policies. The excessive population in China and the rise of various communicable and noncommunicable diseases are majorly driving the pharmaceutical companies in China, making it a prime market in Asia Pacific. For instance, the COVID-19 outbreak in China led to the launch of several drugs to counter the virus. It increased contract manufacturing of drugs, such as lyophilized remdesivir powder, fueling the demand for lyophilized injectables in the country. Due to the pandemic, various market players ramped up the production of certain lyophilized drugs as it ensures safe and prolonged packaging of the drugs. Market players in China have constantly been evolving with organic and inorganic strategies. For instance, WuXi STA—a subsidiary of WuXi AppTec—announced its first parenteral formulation production line at the Wuxi city site. This wholly automatic sterile manufacturing line runs in a complete isolation system with an annual capacity of 2 million units. The automatic parenteral filling line features numerous filling modules and a built-in lyophilizer to fill syringes, vials, and cartridges of a full range of sizes and produce lyophilized powders. Thus, growing pharmaceutical & biopharmaceutical market and increasing initiatives by market players are expected to drive the market during the forecast period.

APAC Lyophilized Injectable Market Revenue and Forecast to 2028 (US$ Million)   

Asia-Pacific Lyophilized Injectable Strategic Insights

Strategic insights for the Asia-Pacific Lyophilized Injectable provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.

Asia-Pacific Lyophilized Injectable Report Scope

Asia-Pacific Lyophilized Injectable Regional Insights

The geographic scope of the Asia-Pacific Lyophilized Injectable refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.

APAC Lyophilized Injectable Market Segmentation      

The APAC lyophilized injectable market is segmented based on type of packaging, type of delivery, indication, end user, and country.

• Based on type of packaging, the APAC lyophilized injectable market is segmented into single-use vials, point-of-care reconstitution, and specialty packaging. The single-use vials segment held the largest market share in 2022.
• In terms of type of delivery, the APAC lyophilized injectable market is categorized into prefilled diluent syringes, single-step devices, proprietary reconstitution devices, and multi-step devices. The prefilled diluent syringes segment held the largest market share in 2022.
• Based on indication, the APAC lyophilized injectable market is segmented into metabolic and oncology conditions, infectious diseases, autoimmune diseases, and others. The metabolic and oncology conditions segment held the largest market share in 2022.
• Based on end user, the APAC lyophilized injectable market is categorized into hospitals, ambulatory surgical centers, specialty clinics, and others. The hospitals segment held the largest market share in 2022.
• Based on country, the APAC lyophilized injectable market is segmented into China, India, Japan, South Korea, Australia, and the Rest of APAC. China dominated the market in 2022.        

Aristopharma Ltd.; Baxter; CordenPharma International; Credence MedSystems, Inc.; Curia Global, Inc.; Jubilant HollisterStier (Jubilant Pharma Limited); Nipro; Recipharm AB; S.G. Biopharm Pvt. Ltd.; and Vetter Pharma are among the leading companies operating in the APAC lyophilized injectable market.